Ian Krop
伊恩·克罗普
MD, PhD
Associate Director of Clinical Research临床研究副主任
👥Biography 个人简介
Ian Krop at Yale Cancer Center is a pioneer in HER2-targeted therapy development. He led pivotal trials of ado-trastuzumab emtansine (T-DM1) and has been instrumental in defining treatment standards for HER2+ metastatic breast cancer. His research spans early-phase drug development to practice-changing phase III studies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
T-DM1 Development
Led the EMILIA and TH3RESA trials of ado-trastuzumab emtansine (T-DM1), establishing it as a standard second-line treatment for HER2+ metastatic breast cancer.
HER2 Therapy Sequencing
Contributed to defining optimal sequencing of HER2-targeted agents in metastatic breast cancer based on mechanism of action and resistance patterns.
Representative Works 代表性著作
Trastuzumab emtansine for HER2-positive advanced breast cancer
NEJM (2012)
EMILIA trial establishing T-DM1 superiority over lapatinib plus capecitabine.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer
NEJM (2012)
CLEOPATRA trial establishing dual HER2 blockade.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 伊恩·克罗普 的研究动态
Follow Ian Krop's research updates
留下邮箱，当我们发布与 Ian Krop（Yale Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment